Evidence map›Paper›PMID 26437251›Full record

ReviewJAMA neurology2015

The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review.

Brian C Callaghan, Raymond S Price, Kevin S Chen, Eva L Feldman

Open access · greenAbstract readReview
In one paragraph

Review in JAMA neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Acute Management of Guillain-Barré Syndrome: A Narrative Review.Archives of internal medicine research · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Diabetic neuropathy: A NRF2 disease?Journal of diabetes · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Brian C CallaghanDepartment of Neurology, University of Michigan, Ann Arbor.
Raymond S PriceDepartment of Neurology, University of Pennsylvania, Philadelphia.
Kevin S ChenDepartment of Neurosurgery, University of Michigan, Ann Arbor.
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor.
University of Michigan–Ann Arbor · USUniversity of Pennsylvania · US

Funding

Integrated Systems Biology Approach to Diabetic Microvascular ComplicationsR24DK082841 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, BROSIUS, FRANK C · 2008 to 2020
$13.1M
Tissue-Specific Metabolic Reprogramming in Diabetic ComplicationsDP3DK094292 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C, BURANT, CHARLES F · 2011 to 2011
$5.5M
UM Clinical Neuroscientist Training ProgramR25NS089450 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALBIN, ROGER L · 2014 to 2023
$1.3M
The Impact of the Metabolic Syndrome on NeuropathyK23NS079417 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CALLAGHAN, BRIAN CHRISTOPHER · 2013 to 2017
$939k
NIDDK NIH HHS DP3 DK094292NIDDK NIH HHS R24 DK082841NINDS NIH HHS K23 NS079417NINDS NIH HHS K23 NS079417-01NINDS NIH HHS R25 NS089450
6 · The paper itself

Abstract

importancePeripheral neuropathy is a prevalent condition that usually warrants a thorough history and examination but has limited diagnostic evaluation. However, rare localizations of peripheral neuropathy often require more extensive diagnostic testing and different treatments.

objectiveTo describe rare localizations of peripheral neuropathy, including the appropriate diagnostic evaluation and available treatments. EVIDENCE REVIEW: References were identified from PubMed searches conducted on May 29, 2015, with an emphasis on systematic reviews and randomized clinical trials. Articles were also identified through the use of the authors' own files. Search terms included common rare neuropathy localizations and their causes, as well as epidemiology, pathophysiology, diagnosis, and treatment.

findingsDiffuse, nonlength-dependent neuropathies, multiple mononeuropathies, polyradiculopathies, plexopathies, and radiculoplexus neuropathies are rare peripheral neuropathy localizations that often require extensive diagnostic testing. Atypical neuropathy features, such as acute/subacute onset, asymmetry, and/or motor predominant signs, are frequently present. The most common diffuse, nonlength-dependent neuropathies are Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and amyotrophic lateral sclerosis. Effective disease-modifying therapies exist for many diffuse, nonlength-dependent neuropathies including Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and some paraprotein-associated demyelinating neuropathies. Vasculitic neuropathy (multiple mononeuropathy) also has efficacious treatment options, but definitive evidence of a treatment effect for IgM anti-MAG neuropathy and diabetic amyotrophy (radiculoplexus neuropathy) is lacking. CONCLUSIONS AND RELEVANCE: Recognition of rare localizations of peripheral neuropathy is essential given the implications for diagnostic testing and treatment. Electrodiagnostic studies are an important early step in the diagnostic evaluation and provide information on the localization and pathophysiology of nerve injury.

Indexed as

Disease ManagementTreatment OutcomeHumansPeripheral Nervous System Diseases

Identifiers

PMID26437251
PMCPMC5087804
OpenAlexW1784990786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.